Product was received for investigation: dhr - the batch record for the perforator 14mm disposable drill, lot j24x28 ,device identifier # (b)(4), manufacturing date of (b)(6)2019 and expiration date of (b)(6)2024 was reviewed and the following was concluded: all assembly process steps, cleaning, functional testing, labeling, packaging, and sterilization process steps were followed and completed with zero non-conformances.Functional test was performed on all (b)(4) units of lot j24x28 was performed according to procedures for ¿codman disposable perforators functional test¿ which tests for perforator disengagement.All units passed the functional requirements.Visual inspection was performed using the unaided eye, and heavy organic matter and dried blood were observed on the returned unit.The sample did not undergo functional testing, and has instead been enrolled in an x-ray study supporting a corrective action which is investigating failure to disengage for the perforator product family.The reported failure mode for this complaint is that the perforator "failed to stop" and therefore may be related to the disengagement of the perforator unit.The complaint issue will continue to be investigated under a corrective action.Between (b)(6)2019 and (b)(6)2020, approximately 2,200 mdrs submitted electronically by integra lifesciences via trackwise, integra's complaint handling system, were not received by cdrh due to a computer system issue.Within this time period, an error with integra's middleware, which facilitates communications between trackwise and the fda system, caused the complaint records to close and indicate we had received an acknowledgement 3 from the fda when we had not.Integra interpreted the acknowledgement as a successful submission; however, subsequent investigation revealed the acknowledgement 3 received was from our middleware and not from the fda (these acknowledgements have been retained as part of the documentation of the mdr).The malfunction was related to the relocation of the trackwise application to a new data center during the transition of integra's corporate headquarters from plainsboro, nj to princeton, nj.Previously, integra had been successfully receiving acknowledgements 1, 2, and 3 from the fda, and our records reflect these acknowledgements, including the date and time stamps.Capa pr (b)(4) and nc 20-011 have been opened by integra to further investigate the nonconformance and develop a corrective action plan.The middleware error has been corrected, and integra has filed mdrs since the correction and verified that the appropriate acknowledgements have been received from the fda.Integra is resubmitting all impacted mdr reports for the time period (b)(4).2019 through (b)(4) 2020.Integra lifesciences contacted (b)(6), director of regulatory programs, office of product evaluation and quality and (b)(6), assistant director, mdr team, office of product evaluation and quality on (b)(6) 2020 to report these issues regarding mdr reports.
|